Every 8-K that NextPlat Corp (NXPL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NXPL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXPL filings page.
NextPlat Corp reported substantially improved results for the quarter ended June 30, 2026. Quarterly revenue was $11.9 million, up approximately 21% sequentially from $9.9 million, driven by growth in contracted healthcare services and a 27% sequential increase in e-commerce revenue to $4.1 million. Contracted pharmacy revenue rose to about $2.2 million from $0.9 million in the prior-year quarter, including higher 340B and medication fulfillment revenue, while total pharmacy prescription revenue declined to $5.6 million from $8.2 million due to lower reimbursement rates and payer mix.
Overall gross margin reached a record 40%, up from 35% in the first quarter of 2026 and 22% a year earlier. Healthcare Operations gross margin increased to 46% and e-Commerce margin to 27%. Net loss attributable to common stockholders narrowed to $144,000 (loss of $0.05 per share) from $1.8 million (loss of $0.69 per share), and management states that excluding a one-time $0.5 million increase in professional fees, the company was profitable in the quarter.
NextPlat ended the period with $11.9 million in cash, working capital of $14.2 million, and no material unsecured debt. The company highlighted growing 340B prescription volumes, new contracted entities, government and military e-commerce sales exceeding $1.75 million year-to-date, a planned pharmacy acquisition in Florida, and an expected nationwide medication fulfillment website launch in the third quarter of 2026.
NextPlat Corp, through indirect subsidiary Progressive Care, LLC, agreed on July 14, 2026 to acquire 100% of the membership interests in Scott’s Pharmacy, LLC, a community pharmacy in Molino, Florida, for $1.5 million in cash, subject to a post-signing inventory adjustment. An initial $50,000 deposit is placed in escrow and credited at closing; at closing the Seller receives the balance and a further $50,000 is held in escrow for 18 months to secure indemnification obligations. Closing is targeted by September 30, 2026, with a one-time extension to October 31, 2026 for an additional $50,000 deposit, and is conditioned on a 30‑day due diligence review, securing a lease for the premises, required consents, regulatory approvals, and customary representations and covenants. The Seller will sign a three‑year Noncompetition Agreement covering Escambia County, Florida.
The acquired pharmacy has served its rural community for over 25 years and generated approximately $5.6 million in 2025 sales with retail margins of about 19%, remaining profitable with positive working capital and no debt. NextPlat’s Healthcare Operations produced about $39.7 million of the Company’s $54.3 million 2025 revenue, and the Company expects roughly 20% organic growth in 2026, supported by higher‑margin 340B and other contracted services. The acquisition is intended to extend PharmcoRx’s footprint into underserved northwest Florida and provide a platform to introduce same‑day delivery, online fulfillment and expanded services for regional providers and patients.
NextPlat Corp reported the results of its 2026 Annual Meeting of stockholders held on June 24, 2026. Stockholders representing 1,685,403 shares of common stock, or about 62.23% of the 2,708,507 shares outstanding as of April 27, 2026, were represented at the meeting.
All director nominees, including Chairman Rodney Barreto and CEO David Phipps, were elected by wide margins, with each receiving over 1.24 million votes in favor. Other proposals described in the company’s April 30, 2026 proxy statement were also approved, including items that received 1,683,296 votes for with 1,516 against and 591 abstentions.
NextPlat Corp reported first quarter 2026 revenue of about $9.9 million, down from roughly $13.9 million a year earlier, mainly from lower healthcare revenue. Despite this, profitability improved as consolidated gross margin reached a quarterly record of about 35%, up from roughly 21%.
Healthcare pharmacy prescription revenue fell to about $4.8 million from $9.5 million, while pharmacy contract revenue rose to about $1.9 million from $1.4 million and e-commerce revenue edged up to about $3.2 million from $3.0 million. Total operating expenses declined about 9% to roughly $4.5 million.
Net loss attributable to common stockholders narrowed to about $1.1 million, or ($0.42) per share, compared with about $1.9 million, or ($0.75) per share, in the prior-year quarter. NextPlat ended March 31, 2026 with roughly $11.0 million in cash, about $14.2 million of working capital and total liabilities of approximately $10.3 million, and management targets positive operating income in the latter half of 2026.
NextPlat Corp shared preliminary expectations for its first quarter 2026 results, pointing to a continuing turnaround driven mainly by contracted healthcare services. The company expects Q1 2026 gross margins to rise to 34+% and operating expenses to decline by 8+% from Q4 2025.
First quarter consolidated gross profit is expected to increase by about 40% versus Q4 2025 as the business shifts toward higher-margin contracted healthcare revenue. NextPlat also reports a record number of added 340B entities, supporting anticipated healthcare services revenue growth and margin expansion through 2026, and is targeting positive operating income in the third quarter.
NextPlat Corp has regained compliance with Nasdaq’s minimum bid price rules, removing a prior delisting risk. The company had previously been notified that its stock traded below $1.00 for 30 straight trading days, triggering a grace period to cure the deficiency.
Nasdaq later confirmed that, for the 10 consecutive business days from April 13, 2026 to April 24, 2026, NextPlat’s closing bid price was at or above $1.00 per share. As a result, Nasdaq issued a compliance letter on April 27, 2026, closed the matter, and NextPlat remains listed on The Nasdaq Capital Market under the ticker “NXPL”.
NextPlat Corp is implementing a 1-for-10 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on April 13, 2026. Every 10 existing shares will be combined into 1 share, with par value staying at $0.0001.
The reverse split will reduce outstanding common shares from approximately 26.9 million to approximately 2.7 million, while authorized shares remain at 50 million. Stock options, warrants and equity plan reserves will be adjusted proportionately, increasing exercise prices and reducing underlying share amounts. No fractional shares will be issued; instead, holders will receive cash based on the Nasdaq closing price on the effective date.
NextPlat’s stock is expected to begin trading on a split-adjusted basis on April 13, 2026 under the symbol “NXPL” with a new CUSIP number. Historical per-share figures, including net loss per share, have been recast to reflect the new share count for 2025 and 2024.
NextPlat Corp reported full-year 2025 revenue of approximately $54.3 million, down 18% from about $66.1 million in 2024, as healthcare prescription volumes declined but e-commerce grew modestly. Healthcare revenue fell to $39.7 million from $52.3 million, driven by fewer prescriptions and lower 340B contract revenue, partly offset by higher reimbursement per script.
e-Commerce revenue increased to $14.6 million from $13.8 million on stronger airtime and hardware sales and favorable foreign exchange. Overall gross margin declined to about 20% from 26%, but total operating expenses were cut roughly in half to $19.9 million from $40.0 million, reflecting cost reductions and the absence of a prior-year impairment loss. Net loss attributable to common stockholders narrowed to approximately $11.7 million, or $0.44 per share, from $13.4 million, or $0.65 per share. The company ended 2025 with about $13.7 million in cash and roughly $15.0 million in working capital.
NextPlat Corp is implementing a 1-for-10 reverse stock split of its common stock to address Nasdaq’s minimum bid price requirement. At 12:01 a.m. Eastern Time on April 6, 2026, every 10 shares will be combined into one share, reducing outstanding common shares from 27,026,215 to approximately 2,702,621, with cash paid for fractional shares. Stockholders approved the reverse split at a special meeting where 15,510,728 shares voted, representing about 57.5% of the 26,976,215 shares outstanding as of March 16, 2026, and the proposals received strong support. The split affects all holders uniformly, keeps authorized share counts unchanged, and proportionately adjusts equity incentive plans and outstanding options and warrants.
NextPlat Corp entered into a formal Employment Agreement with Amanda L. Ferrio on January 9, 2026, confirming her role as Chief Financial Officer for an initial three-year term, with potential one-year renewals at the CEO’s discretion.
The Agreement provides a base salary of $225,000 per year, a monthly auto allowance of $650, eligibility for annual cash bonuses, and participation in equity incentive plans, along with company-paid health insurance and other standard benefits. If Ms. Ferrio is terminated without cause or resigns for good reason, she is entitled to six months of base salary and up to six months of COBRA premiums, subject to signing a release. The Agreement also includes customary confidentiality, non-competition, and non-solicitation covenants during employment and for specified periods after it ends.
NextPlat Corp filed a current report describing that it has issued a press release announcing its financial results for the quarter ended September 30, 2025. The company notes that this press release is furnished as Exhibit 99.1 to the report and relates to its results of operations and financial condition.
The report clarifies that the information provided under Item 2.02 and in the exhibit is furnished rather than filed, meaning it is not automatically subject to certain liability provisions under U.S. securities laws unless specifically incorporated into other filings. NextPlat’s common stock and warrants continue to trade on The Nasdaq Stock Market under the symbols NXPL and NXPLW, respectively.
NextPlat Corp reported that Nasdaq granted a second 180‑day grace period to regain the minimum bid price requirement. The new deadline is April 27, 2026, during which the company must have a closing bid of at least $1.00 for a minimum of 10 consecutive business days (which Nasdaq may extend to 20 days) to cure the deficiency.
The determination was based on NextPlat meeting all other initial listing standards and notifying Nasdaq that it intends to pursue a reverse stock split if needed. The company’s common stock will continue to trade on the Nasdaq Capital Market while it works toward compliance.
NextPlat Corp announced a leadership change in finance. On October 13, 2025, Chief Financial Officer Cecile Munnik stepped down and will assist during a transition, including through the filing of the quarterly report for the period ended September 30, 2025.
The Board appointed Amanda L. Ferrio as Chief Financial Officer effective immediately. Ferrio, 37, has led accounting and finance at the company’s Progressive Care subsidiary since 2022 and brings over 15 years of experience. Her annual base salary was set at $225,000. The company reported no related-party or selection arrangements. A press release dated October 14, 2025 announces the appointment.
NextPlat Corp disclosed that its Board appointed David Phipps as Chief Executive Officer (appointment announced September 3, 2025) and the Compensation Committee approved changes on September 24, 2025. His annual base salary was increased to $450,000 and he received a one-time grant of 200,000 common shares under the company's 2021 Incentive Plan; those shares fully vested on the grant date. The company filed an amendment to his employment agreement reflecting these terms.